Scholarlink

<p>Cervical cancer (CC) is a prevalent malignancy among women worldwide with considerable incidence and mortality. Recent studies have suggested that the Rab-interacting lysosomal protein-like 2 (RILPL2) acts as a tumor suppressor and plays an inhibitory role in multiple human cancers. However, the potential effect of RILPL2 in CC remains unclear. In our investigation, we found that RILPL2 was downregulated in CC samples and was associated with a favorable outcome. Further findings indicated the interaction between RILPL2 and lactate dehydrogenase A (LDHA), a crucial player regulating glycolysis. Mechanistically, RILPL2 reduced LDHA stability by recruiting TRIM21 to facilitate K48-linked ubiquitination chains of LDHA and promoting LDHA degradation, thereby blocking glycolytic reprogramming and, in turn, inhibiting CC progression and development. Moreover, RILPL2-mediated inhibition of the glycolytic pathway could restrain lactate production, which abolished H3K18 lactylation to induce the downregulation of SOX9 and SMYD2. Consequently, our results suggested that RILPL2 may serve as a potential therapeutic target for the treatment of CC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RILPL2 suppresses metabolic reprogramming and progression of cervical cancer by attenuating LDHA protein stability and inhibiting H3K18 lactylation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月4日

查看全文
  • Yujing Shi,
  • Zhaoyue Zhang,
  • Jin Liu,
  • Caiqiang Zhu,
  • Gefenqiang Shen,
  • Meng Tian,
  • Liang Liang,
  • Jinhui Liu,
  • Xiaoke Di

摘要

Cervical cancer (CC) is a prevalent malignancy among women worldwide with considerable incidence and mortality. Recent studies have suggested that the Rab-interacting lysosomal protein-like 2 (RILPL2) acts as a tumor suppressor and plays an inhibitory role in multiple human cancers. However, the potential effect of RILPL2 in CC remains unclear. In our investigation, we found that RILPL2 was downregulated in CC samples and was associated with a favorable outcome. Further findings indicated the interaction between RILPL2 and lactate dehydrogenase A (LDHA), a crucial player regulating glycolysis. Mechanistically, RILPL2 reduced LDHA stability by recruiting TRIM21 to facilitate K48-linked ubiquitination chains of LDHA and promoting LDHA degradation, thereby blocking glycolytic reprogramming and, in turn, inhibiting CC progression and development. Moreover, RILPL2-mediated inhibition of the glycolytic pathway could restrain lactate production, which abolished H3K18 lactylation to induce the downregulation of SOX9 and SMYD2. Consequently, our results suggested that RILPL2 may serve as a potential therapeutic target for the treatment of CC.